REDWOOD CITY, Calif., July 16, 2014 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today announced that patient dosing has begun in the randomized, placebo-controlled Phase 2 portion of the company's " ALPINE" ( Antibody therapy in first- Line Pancreatic cancer Investigating anti- Notch Efficacy and safety) clinical trial of its anti-Notch 2/3 cancer stem cell antibody, tarextumab (OMP-59R5), being studied for the treatment of pancreatic cancer.
Tarextumab is being tested in combination with Abraxane ® (paclitaxel protein-bound particles for injectable suspension) (albumin bound) plus gemcitabine in patients with previously untreated stage IV pancreatic cancer. The ALPINE trial is being conducted at up to 30 sites in the U.S. and is expected to enroll approximately 124 patients. The Phase 2 clinical trial will compare the progression-free survival (PFS) of 15 mg/kg tarextumab administered every two weeks versus placebo in combination with Abraxane plus gemcitabine in all patients. Additionally, PFS will be assessed using a predictive biomarker for high tumor Notch3 expression. Secondary and exploratory endpoints, including overall survival and overall response rate, pharmacokinetics, safety and other biomarkers, will also be evaluated.
"Pancreatic cancer remains one of the most challenging malignances, with one-year survival rates at 20% for newly-diagnosed patients," said Eileen M. O'Reilly, M.D., of Memorial Sloan Kettering Cancer Center, a Principal Investigator for ALPINE. "Tarextumab has demonstrated a promising emerging therapeutic profile in early testing, and the continuing ALPINE trial will yield further insight into whether this compound can provide improved treatment options for pancreatic cancer patients.""Tarextumab has been well tolerated in combination with standard chemotherapies. Treatment-related adverse events were mostly mild and moderate and easily managed. Encouraging signs of anti-tumor activity have also been observed, with a number of patients achieving partial responses or stable disease in the Phase 1b portion of the ALPINE study," said Jakob Dupont, M.D., Chief Medical Officer of OncoMed. "We are excited to advance tarextumab into the first OncoMed randomized, placebo-controlled Phase 2 study designed to measure its efficacy in patients with advanced pancreatic cancer."
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV